Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Key facts
- Where
- Ann Arbor, Baltimore, Birmingham, Boston, Burlington, Chapel Hill, Chicago, Columbus, Dallas, Denver, Gainesville, Lebanon, Los Angeles, New York, Pittsburgh, San Diego, and Seattle, United StatesSee the 18 sites
Where in United States
- University of MichiganAnn Arbor, United StatesNo longer taking part
- John Hopkins UniversityBaltimore, United StatesNo longer taking part
- University of AlabamaBirmingham, United StatesNo longer taking part
- Boston Childrens HospitalBoston, United StatesNo longer taking part
- University of VermontBurlington, United StatesNo longer taking part
- University of North Carolina at Chapel HillChapel Hill, United StatesNo longer taking part
- Northwestern UniversityChicago, United StatesNo longer taking part
- Nationwide Children's HospitalColumbus, United StatesNo longer taking part
- Southwestern Medical Center at DallasDallas, United StatesNo longer taking part
- Childrens hospital coloradoDenver, United StatesNo longer taking part
- National Jewish HealthDenver, United StatesNo longer taking part
- University of FloridaGainesville, United StatesNo longer taking part
- Dartmouth Hitchcock Medical CenterLebanon, United StatesNo longer taking part
- Children's Hospital of Los AngelesLos Angeles, United StatesNo longer taking part
- Columbia UniversityNew York, United StatesNo longer taking part
- University of Pittsburgh Medical CenterPittsburgh, United StatesNo longer taking part
- University of CaliforniaSan Diego, United StatesNo longer taking part
- University of WashingtonSeattle, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Jewish Health
- Trial code
- NCT06262282
- Record updated
- 21 May 2025
- Original description
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.Read full original descriptionShow less
A Prospective Standardized Assessment of People With Cystic Fibrosis and Non-tuberculosis Mycobacteria Pulmonary Disease Undergoing Treatment With Mycobacteriophage (POSTSTAMP)
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.
Inclusion: Written informed consent (and assent when applicable) obtained from participant or participant's legal representative; Enrolled in the CFF Patient Registry (CFF PR); Be willing to adhere to study procedures in the context of clinical care, and other protocol requirements; Male or female participant ≥ 6 years of age at enrollment who are able to reliably expectorate sputum and/or willing to undergo sputum induction (if necessary); Diagnosis of CF consistent with the 2017 CFF Guidelines; NTM pulmonary disease on treatment with guideline-based antibiotics for >12 months without consistent conversion of airway cultures to negative; Physician intention to treat NTM with phage therapy (if susceptible); Be willing and able to continue guideline-based antibiotics for NTM concurrent with phage; Documentation of a sufficient number of NTM cultures with a sufficient proportion of positive cultures in the interval 12 months prior to initiation of phage to allow for a within-subject power ≥0.80 to detect a difference in the percent positive NTM cultures in the interval 6-18 months following initiation of phage.
Exclusion: Prior or ongoing phage therapy for the species of NTM under consideration; History of solid organ or hematological transplantation; Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives; Pregnant or breastfeeding.